Instrument Inactif

Communiqués Pharmacyclics, Inc.

Actions

US7169331060

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

05/03/15	Wall Street se reprend un peu dans un climat d'attente	RE
05/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente	RE

Communiqués

07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
07/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
07/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU
07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia Patients in Phase III RESONATETM-2 Trial	PU
07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Improved Survival for Treatment–Naïve Chronic Lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial	PU
21/04/15	Pharmacyclics : Stock Updates on Biotech -- Celgene, Amgen, PDL BioPharma, Amarin, and Pharmacyclics	PR
01/04/15	Pharmacyclics : Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers	PR
18/03/15	PHARMACYCLICS : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU
10/03/15	Pharmacyclics : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
09/03/15	PHARMACYCLICS : SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to AbbVie	BU
09/03/15	Pharmacyclics : INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie	BU
09/03/15	Pharmacyclics : Ryan & Maniskas, LLP : Announces Investigation of Pharmacyclics Inc.	PR
07/03/15	Pharmacyclics : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Pharmacyclics, Inc. - PCYC	PR
06/03/15	Pharmacyclics : Harwood Feffer LLP : Announces Investigation of Pharmacyclics, Inc.	PR
05/03/15	Pharmacyclics : EQUITY ALERT: The Rosen Law Firm Announces Investigation of Pharmacyclics Inc. Concerning its Proposed Sale to AbbVie Inc. – PCYC	BU
05/03/15	Pharmacyclics : SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Pharmacyclics, Inc. - PCYC	PR
05/03/15	Pharmacyclics : INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie -- PCYC	BU
05/03/15	Pharmacyclics : AbbVie : to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise	PR
27/02/15	Pharmacyclics : Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases	PR
18/02/15	Pharmacyclics : Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Updates	PU
17/02/15	Pharmacyclics : IMBRUVICA® (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant	PU
12/02/15	Pharmacyclics : Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results	PR
12/02/15	Pharmacyclics : Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics	PR